Tezspire FDA Approval History
Last updated by Judith Stewart, BPharm on Dec 20, 2021.
FDA Approved: Yes (First approved December 17, 2021)
Brand name: Tezspire
Generic name: tezepelumab-ekko
Dosage form: Injection
Company: Amgen and AstraZeneca
Treatment for: Asthma
Tezspire (tezepelumab-ekko) is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
- Tezspire works by inhibiting the action of TSLP, a cytokine that is released in response to triggers associated with asthma exacerbations.
- Tezspire is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.
- Tezspire is administered via subcutaneous injection once every four weeks.
- Common adverse reactions include pharyngitis, arthralgia, and back pain.
- Tezspire is also in development for other potential indications including chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria and eosinophilic esophagitis (EoE).
Development timeline for Tezspire
|Feb 2, 2023||Approval Tezspire Approved for Self-Administration in the U.S. With a New Pre-filled Pen|
|Dec 17, 2021||Approval FDA Approves Tezspire (tezepelumab) for Severe Asthma|
|Oct 8, 2021||Tezepelumab Granted Orphan Drug Designation in the US for Eosinophilic Esophagitis|
|Sep 5, 2021||New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps|
|Jul 7, 2021||Tezepelumab Granted Priority Review By U.S. FDA|
|May 13, 2021||New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients|
|May 10, 2021||Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA|
|Feb 26, 2021||Tezepelumab is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients|
|Dec 21, 2020||Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma|
|Nov 10, 2020||Tezepelumab NAVIGATOR Phase III Trial Met Primary Endpoint of a Statistically Significant and Clinically Meaningful Reduction in Exacerbations in a Broad Population of Patients with Severe Asthma|
|Nov 9, 2020||Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma|
|Sep 6, 2018||Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype|
|Sep 6, 2017||Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.